Your browser doesn't support javascript.
loading
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.
Moreau, P; Joshua, D; Chng, W-J; Palumbo, A; Goldschmidt, H; Hájek, R; Facon, T; Ludwig, H; Pour, L; Niesvizky, R; Oriol, A; Rosiñol, L; Suvorov, A; Gaidano, G; Pika, T; Weisel, K; Goranova-Marinova, V; Gillenwater, H H; Mohamed, N; Aggarwal, S; Feng, S; Dimopoulos, M A.
Afiliação
  • Moreau P; University of Nantes, Nantes, France.
  • Joshua D; Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
  • Chng WJ; National University Cancer Institute, National University Health System; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
  • Palumbo A; University of Torino, Torino, Italy.
  • Goldschmidt H; Heidelberg Medical University, Heidelberg, Germany.
  • Hájek R; University Hospital Ostrava, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  • Facon T; CHRU Lille Hôpital Claude Huriez, Lille, France.
  • Ludwig H; Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria.
  • Pour L; University Hospital Brno, Brno, Czech Republic.
  • Niesvizky R; Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA.
  • Oriol A; Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.
  • Rosiñol L; Hospital Clínic de Barcelona, Barcelona, Spain.
  • Suvorov A; Hematological Department, First Republican Clinical Hospital of Udmurtia, Izhevsk, Russia.
  • Gaidano G; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
  • Pika T; Department of Hematooncology, University Hospital Olomouc, Olomouc, Czech Republic.
  • Weisel K; Universitätsklinikum Tübingen, Tübingen, Germany.
  • Goranova-Marinova V; University Multiprofile Hospital for Active Treatment 'Sv. Georgi' and Medical University, Plovdiv, Bulgaria.
  • Gillenwater HH; Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA.
  • Mohamed N; Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA.
  • Aggarwal S; Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA.
  • Feng S; Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA.
  • Dimopoulos MA; National and Kapodistrian University of Athens, Athens, Greece.
Leukemia ; 31(1): 115-122, 2017 01.
Article em En | MEDLINE | ID: mdl-27491641
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Dexametasona / Terapia de Salvação / Bortezomib / Mieloma Múltiplo Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Dexametasona / Terapia de Salvação / Bortezomib / Mieloma Múltiplo Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: França